Anti-NLGN3/ HNL3 monoclonal antibody

Anti-NLGN3/ HNL3 antibody for FACS & in-vivo assay

Target products collectionGo to NLGN3/NLGN3 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0888-Ab-1/ GM-Tg-hg-MP0888-Ab-2Anti-Human NLGN3 monoclonal antibodyHuman
GM-Tg-rg-MP0888-Ab-1/ GM-Tg-rg-MP0888-Ab-2Anti-Rat NLGN3 monoclonal antibodyRat
GM-Tg-mg-MP0888-Ab-1/ GM-Tg-mg-MP0888-Ab-2Anti-Mouse NLGN3 monoclonal antibodyMouse
GM-Tg-cynog-MP0888-Ab-1/ GM-Tg-cynog-MP0888-Ab-2Anti-Cynomolgus/ Rhesus macaque NLGN3 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0888-Ab-1/ GM-Tg-felg-MP0888-Ab-2Anti-Feline NLGN3 monoclonal antibodyFeline
GM-Tg-cang-MP0888-Ab-1/ GM-Tg-cang-MP0888-Ab-2Anti-Canine NLGN3 monoclonal antibodyCanine
GM-Tg-bovg-MP0888-Ab-1/ GM-Tg-bovg-MP0888-Ab-2Anti-Bovine NLGN3 monoclonal antibodyBovine
GM-Tg-equg-MP0888-Ab-1/ GM-Tg-equg-MP0888-Ab-2Anti-Equine NLGN3 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0888-Ab-1/ GM-Tg-hg-MP0888-Ab-2; GM-Tg-rg-MP0888-Ab-1/ GM-Tg-rg-MP0888-Ab-2;
GM-Tg-mg-MP0888-Ab-1/ GM-Tg-mg-MP0888-Ab-2; GM-Tg-cynog-MP0888-Ab-1/ GM-Tg-cynog-MP0888-Ab-2;
GM-Tg-felg-MP0888-Ab-1/ GM-Tg-felg-MP0888-Ab-2; GM-Tg-cang-MP0888-Ab-1/ GM-Tg-cang-MP0888-Ab-2;
GM-Tg-bovg-MP0888-Ab-1/ GM-Tg-bovg-MP0888-Ab-2; GM-Tg-equg-MP0888-Ab-1/ GM-Tg-equg-MP0888-Ab-2
Products NameAnti-NLGN3 monoclonal antibody
Formatmab
Target NameNLGN3
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-NLGN3 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species NLGN3/ HNL3 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0888
    Target NameNLGN3
    Gene ID54413,245537,171297,574216,491947,101090921,511251,100055823
    Gene Symbol and SynonymsA230085M13Rik,HNL3,NL3,NLG3,NLGN3
    Uniprot AccessionQ9NZ94,Q62889,Q8WMH2
    Uniprot Entry NameNLGN3_HUMAN,NLGN3_MACMU,NLGN3_RAT
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000196338
    Target ClassificationN/A

    The target: NLGN3, gene name: NLGN3, also named as HNL3. This gene encodes a member of a family of neuronal cell surface proteins. Members of this family may act as splice site-specific ligands for beta-neurexins and may be involved in the formation and remodeling of central nervous system synapses. Mutations in this gene may be associated with autism and Asperger syndrome. Multiple transcript variants encoding distinct isoforms have been identified for this gene. [provided by RefSeq, Oct 2009].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.